Genomenon, Inc.

Ann Arbor, MI · Founded 2014 · Medtech · Private

Mastermind Genomic Search Engine - a database and software platform that automatically indexes medical literature to organize disease, gene, and variant information for clinical interpretation of geno

Claim this profile

Follows are private to you and power your alerts

Updated · genomenon.com

Sector
Medtech
Headquarters
Ann Arbor, MI
Founded
2014
Latest Form D
$5.5M, May 2024
Total capital
$33.2M
Federal grants
$4.4M
6 awards · 2017–2022
6.0× sector median 1 award
Private capital raised
$28.8M
4 Form D · last May 2024
29 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
1 pending

Capital timeline

20152017201920212023FEDERAL ↑EQUITY ↓Cumulative $33.2M$224K$748K$737K$153K$1.7M$855K1st Form D$446K2nd Form D$2.9M3rd Form D$20M
20152017201920212023FEDERAL ↑EQUITY ↓Cumulative $33.2M$748K$737K$1.7M$855K2nd Form D$2.9M

Latest events

  • Private capital raisedForm D · SEC · 4th filing$5.5M
  • Federal grantHealth and Human S · Phase II · Micropublications for Automating Genome Sequence Variant Interpretation from Medical Literature$855K
  • Private capital raisedForm D · SEC · 3rd filing$20M
  • Federal grantHealth and Human S · Phase II · Micropublications for Automating Genome Sequence Variant Interpretation from Medical Literature$1.7M
  • Private capital raisedForm D · SEC · 2nd filing$2.9M
  • Federal grantHealth and Human S · Phase I · Micropublications for Automating Genome Sequence Variant Interpretation from Medical Literature$153K
  • Federal grantHealth and Human S · Phase II · Commercial Software Using High-throughput Computational Techniques to Improve Genome Analysis$737K
  • Private capital raisedForm D · SEC · 1st filing$446K
Show 2 earlier federal awards
  • Federal grantHealth and Human S · Phase II · Commercial Software Using High-throughput Computational Techniques to Improve Genome Analysis$748K
  • Federal grantHealth and Human S · Phase II · Commercial Software Using High-throughput Computational Techniques to Improve Genome Analysis$224K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing in Medtech · 4531 companies

Line = median
  • Federal contractsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Mark KielResearcherExecutive Officer, DirectorLinked by $1.7M in grants as PI
  • Charles MoretDirectorNamed in SEC Form D filings
  • David GregorkaDirectorNamed in SEC Form D filings
  • Eli SalembierExecutive Officer, DirectorNamed in SEC Form D filings
  • Michael GrossDirectorNamed in SEC Form D filings
  • Michael KleinExecutive Officer, DirectorNamed in SEC Form D filings
Show all 11 people
  • Patricia GlazaDirectorNamed in SEC Form D filings
  • Sam GlobusExecutive OfficerNamed in SEC Form D filings
  • Sean KearneyExecutive OfficerNamed in SEC Form D filings
  • Sonya SepahbanDirectorNamed in SEC Form D filings
  • Steve SchwartzExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 1
  • PendingSystems And Methods For Gene Variant Grouping And VisualizationUSPTOApplication 17917751

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .